醫(yī)學(xué)免費(fèi)論文:活血通脈片對(duì)老年冠心病的療效觀察及機(jī)制探討
【摘要】 目的觀察活血通脈片治療老年冠心病心絞痛的臨床療效,初步探索其作用機(jī)制。方法將80例老年冠心病心絞痛患者隨機(jī)分為活血通脈片組(40例,常規(guī)西藥加活血通脈片)與單純西藥治療組(40例,單用西藥治療),觀察治療前后血漿內(nèi)皮素(ET)與降鈣素基因相關(guān)肽(CGRP)含量,臨床癥狀和心電圖的變化,并選擇30例門(mén)診健康體檢者為正常組進(jìn)行對(duì)比。結(jié)果治療前與治療后兩組患者ET明顯高于健康人(P<0.01),CGRP明顯低于健康人(P<0.01),活血通脈組臨床療效總有效率及心電圖療效總有效率明顯優(yōu)于西藥對(duì)照組(P<0.01);兩組患者ET均明顯降低,CGRP明顯升高,但是活血通脈組優(yōu)于西藥對(duì)照組(P<0.01)。結(jié)論活血通脈片可抑制血漿ET過(guò)量釋放,同時(shí)提高血漿CGRP濃度,具有良好的抗心肌缺血作用,對(duì)老年冠心病心絞痛有較好的療效。
【關(guān)鍵詞】 活血通脈片 老年冠心病 心絞痛
Effective Observation and Mechanism of HXTMT on Senile Coronary Heart Disease
JIANG Yurong, YANG Jian, LI Song, LI Ying^, LV Jianqiong
(The First College of Clinical Medical Science, China Three Gorges University&The Department of Cardiology, YiChang Central People's Hospital, Yichang, Hubei 443003, China)
Abstract:ObjectiveTo observe the curative effect of HXTMT on senile coronary heart disease(CHD) and its mechanism. MethodsEighty patients were divided into two groups randomly. Group Ⅰ(n=40) was treated by HXTMT adding up general medicine;Group Ⅱ(n=40)only by common medicine. The changes of the ET and CGRP contents before and after treatment were observed,and the symtpoms and ECG were compered with healthy people(n=30). ResultsThe ET contents of group ⅠandⅡwere both higher than healthy people before and after treatment (P<0.01).CGRP was significantly lower than the healthy people, but the group Ⅰwas higher than to the group Ⅱ in general effection and ECG change. ConclusionHXTMT can inhibit the release of serum ET and increase the serum CGRP. There is good effect on ischemis myocardiopathy in CHD.
Key words:HXTMT; Coronary artery disease; Angina
冠心病是老年人常見(jiàn)病。隨著人口老齡化,冠心病已成為危及人類(lèi)健康的主要疾病之一,所以對(duì)冠心病的有效治療成了國(guó)內(nèi)外非常關(guān)注的問(wèn)題。血漿內(nèi)皮素(ET)和降鈣素基因相關(guān)肽(CGRP)是近年來(lái)發(fā)現(xiàn)的一對(duì)效應(yīng)相反的血管活性物質(zhì),ET加重心肌缺血,CGRP有拮抗ET的作用,對(duì)缺血心肌有保護(hù)作用;钛}片具有益氣活血、通經(jīng)止痛之功,對(duì)冠心病心絞痛具有一定療效,對(duì)ET和CGRP的影響已成為當(dāng)今研究的熱點(diǎn)。為了解活血通脈片治療老年冠心病心絞痛的臨床療效和治療機(jī)理,我們對(duì)80例老年心絞痛患者作了臨床研究,并以ET和CGRP等作為判斷療效的治療指標(biāo),F(xiàn)報(bào)道如下醫(yī).學(xué).全.在.線(xiàn)m.52667788.cn。
1 材料與方法
1.1 病例資料根據(jù)WHO1979年“缺血性心臟病的命名及診斷標(biāo)準(zhǔn)”[1]選擇老年心絞痛患者80例及健康人30例,將心絞痛患者隨機(jī)分為兩組,其中活血通脈組40例,男23例,女17例,年齡55~75歲,平均(64.1±6.8)歲,病程1.0~4.6年,平均2.4年,其中穩(wěn)定型心絞痛18例,不穩(wěn)定型心絞痛22例;單純西藥組40例,男22例;女18例,年齡54~72歲,平均(61.4±5.1)歲,病程1.2~4.1年,平均2.1年,其中穩(wěn)定型心絞痛19例,不穩(wěn)定型心絞痛21例。兩組病例在性別、年齡、病情等方面比較均無(wú)顯著差異(P>0.05),具有可比性。另選擇30例門(mén)診健康體檢者作比較,其中男16例,女14例,年齡55~65歲平均(60.5±5.8)歲。